retatrutide clinical trial outcomes Lilly's triple agonist delivers up to 71.2 lbs of weight loss Lilly orforglipron oral GLP-1 phase
Description
If youre considering treatment with GLP-1 agonists, review your plans policies
Int J Obes (Lond) 42:964973 Pan A, Claro M, Molina-Andujar A et al (2023) Bariatric surgery outcomes in patients with chronic kidney disease
Individual needs vary enormously
In the SURMOUT-1 trial 2,539 patients underwent randomization to tirzepatide or placebo and were followed for 72 weeks demonstrating up to 20.9% weight reduction with maintenance dosing versus 3.1% in the placebo group for a net 17.8% weight reduction [35]
For those who have SIBO and/or IBS, these foods can exacerbate the problem by feeding overgrown gut bacteria
